intellectual property


Sign-on letter from India against IPR on seed
A mega free trade agreement, like RCEP that undermines farmers’ seed freedoms in a mega diverse country, with seed diversity and farmers’ knowledge is unacceptable, say over 50 groups and citizens
How drug prices could derail new trade pact to replace NAFTA
Democrats in Congress contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump's signature causes.
Provision that could raise drug costs emerges as key obstacle to NAFTA approval
Some Democrats in the US, like Canada’s generic drug industry, warn that the new biologics rule would keep drug prices high by requiring citizens to wait longer before they can get their hands on lower-cost similar drugs known as biosimilars.
More than 70 US health, consumer and other groups demand elimination of NAFTA 2.0 terms that would lock in high US medicine prices
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
We can't afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
The IP implications of the USMCA: Who needs to do what
The USMCA most closely reflects US IP laws, subjecting the US to almost no revisions of its current domestic intellectual property laws.
IP licence, trademarks and ISDS: Bridgestone v. Panama
Can an intellectual property right or a license authorizing its use be deemed an ‘investment’ under bilateral investment treaties?
Free trade agreement with Indonesia to be signed in Jakarta on 16 December
Indonesia - EFTA trade deal will be signed, 98 per cent of Swiss exports to Indonesia will be exempt from customs duties over the coming years.
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
Japan to extend copyright period on works including novels and paintings to 70 years on Dec. 30
The copyright period on works such as novels and paintings in Japan is set to be extended to 70 years after the authors’ deaths, from the current 50 years, as part of legislation to approve the TPP.